Eli Lilly's Taltz bests J&J rival Tremfya in head-to-head psoriasis tilt

Eli Lilly
Lilly's Taltz helped a higher proportion of psoriasis patients in a phase 4 study achieve completely clear skin. (Eli Lilly)

It wasn’t all that long ago that Johnson & Johnson was touting head-to-head results for its psoriasis drug Tremfya against Novartis’ blockbuster Cosentyx. But now, a different rival has topped Tremfya in a showdown of its own.

Tuesday, Eli Lilly said Taltz had topped the J&J med at achieving total skin clearance in psoriasis patients after 12 weeks of treatment. In a phase 4 study pitting the two drugs against one another, Taltz helped a higher proportion of patients hit that mark, as measured by the commonly used Psoriasis Area Severity Index (PASI).

Exactly how many patients reached the target remains to be disclosed, so it’s not yet clear how big Taltz’s win actually was. But the product also topped Tremfya at each measured interval between the start of treatment and Week 12, Lilly said.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

RELATED: Johnson & Johnson’s Tremfya tops Novartis blockbuster Cosentyx in head-to-head psoriasis showdown

“Research shows that patients want clear skin and rapid improvements,” Lotus Mallbris, Lilly VP of immunology development, said in a statement. "Head-to-head data like these are important and will help inform individual treatment goal discussions between healthcare providers and their patients,” Andrew Blauvelt, dermatologist and president of Oregon Medical Research Center, added.

Lilly certainly hopes so. It’s working to improve on the $606.3 million in global sales that Taltz pulled in through the first half of the year—a performance that puts it well on track to break the blockbuster barrier. The therapy came just short of it last year, generating $937.5 million.

RELATED: Can new data give Lilly's Taltz one head start on Novartis' Cosentyx?

While Lilly’s treatment has come a long way since its 2016 debut, it hasn’t been an easy fight. It went up against Novartis’ in-class powerhouse Cosentyx, which beat it to market, as well as anti-TNF giants including AbbVie’s Humira and Amgen’s Enbrel. Later, additional competitors—including Tremfya, which picked up a head-to-head psoriasis victory of its own last year against Cosentyx—joined the mix.

The Indianapolis drugmaker isn’t just counting on psoriasis for sales, though, and neither are its nemeses. It also bears an approval in psoriatic arthritis, and it’s chasing a nod in non-radiographic axial spondyloarthritis, too.

Suggested Articles

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.